New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies

J Invest Dermatol. 2021 Oct;141(10):2328-2337. doi: 10.1016/j.jid.2021.02.743. Epub 2021 Apr 19.


Although psoriasis and psoriatic arthritis (PsA) have been classically considered to be diseases of the skin and joints, respectively, emerging evidence suggests that a combination of innate and environmental factors creates widespread immune dysfunction, affecting multiple organ systems. A greater understanding of the pathogenesis of psoriasis and the systemic effects of psoriatic inflammation has allowed for the development of new, more effective treatments. The second portion of this two-part review series examines the comorbidities associated with psoriasis and PsA as well as the most recent advances in targeted systemic therapies for these conditions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Arthritis, Psoriatic / drug therapy*
  • Cardiovascular Diseases / etiology
  • Comorbidity
  • Humans
  • Molecular Targeted Therapy
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Psoriasis / psychology